Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children
Status:
Terminated
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
Hypothesis: pegfilgrastim at 300 µg/kg in hematological steady state provides an efficient
stem cell mobilization in children with malignancies
Design: phase 2 study.
Judgment criterion: percentage of children achieving at least 5x10e6 CD34 cells with a
standard apheresis (less than 2 blood volume processed)